Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Fujifilm Cellular Dynamics Launches Opsis Therapeutics

Published 09/29/2016, 10:25 PM
Updated 07/09/2023, 06:31 AM
XRX
-
CAJPY
-
PLAB
-
FUJIY
-

Cellular Dynamics International, Inc. (‘CDI’), a recently acquired business arm of FUJIFILM Holdings Corporation (OTC:FUJIY) , launched a new venture, ‘Opsis Therapeutics’. The move is in sync with Fujifilm’s aim to underpin regenerative medicine business over time.

Formed on Jul 31, 2016, Opsis Therapeutics would be focusing on inventing and developing medicines to restore vision to patients suffering from variable retinal diseases. The venture is in partnership with David Gamm, M.D., Ph.D. and is aimed at developing novel cell therapeutic programs. Gamm is a global leader and pioneer in the transplantation and differentiation of iPSC (induced pluripotent stem cell)-based retinal cells.

Cellular Dynamics has expertise in the creation and development of iPSC-derived cell therapeutics. In partnership with Opsis Therapeutics, CDI aims to expand its cGMP iPSC bank for reinforcing its therapeutics pipeline. This would aid in the creation of first-in-class cell therapies, required for the treatment of various retinal diseases.

Fujifilm Regenerative Medicine Business

Fujifilm offers diversified categories of products in the market. In order to sustain or boost market competency, premium technology companies, like Fujifilm, Photronics Inc. (NASDAQ:PLAB) , Xerox Corporation (NYSE:XRX) and Canon Inc. (NYSE:CAJ) , undertake incessant efforts to solidify or widen their existing product portfolios.

In Mar 2015, Fujifilm acquired CDI for roughly $307 million. This investment was made by the company to fortify its regenerative medicine business. Cellular Dynamics has formed a Cooperative Research and Development Agreement with the U.S. National Eye Institute for developing medicines required for the treatment of retinal degenerative disease. We perceive that CDI’s new partnership venture will further strengthen its iPSC-derived cell therapeutics solutions’ expertise.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>



XEROX CORP (XRX): Free Stock Analysis Report

FUJIFILM HLDGS (FUJIY): Free Stock Analysis Report

CANON INC ADR (CAJ): Free Stock Analysis Report

PHOTRONICS INC (PLAB): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.